ATE540110T1 - Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt - Google Patents
Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfaltInfo
- Publication number
- ATE540110T1 ATE540110T1 AT05819866T AT05819866T ATE540110T1 AT E540110 T1 ATE540110 T1 AT E540110T1 AT 05819866 T AT05819866 T AT 05819866T AT 05819866 T AT05819866 T AT 05819866T AT E540110 T1 ATE540110 T1 AT E540110T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- chunk
- certain embodiments
- generating
- molecular diversity
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000000644 propagated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62658904P | 2004-11-11 | 2004-11-11 | |
| US69730705P | 2005-07-06 | 2005-07-06 | |
| PCT/US2005/040748 WO2006053131A1 (en) | 2004-11-11 | 2005-11-11 | Ladder assembly and system for generating diversity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540110T1 true ATE540110T1 (de) | 2012-01-15 |
Family
ID=35789369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05819866T ATE540110T1 (de) | 2004-11-11 | 2005-11-11 | Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7485423B2 (de) |
| EP (1) | EP1817413B1 (de) |
| JP (1) | JP2008519602A (de) |
| AT (1) | ATE540110T1 (de) |
| CA (1) | CA2590245A1 (de) |
| WO (1) | WO2006053131A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US10148285B1 (en) | 2012-07-25 | 2018-12-04 | Erich Schmitt | Abstraction and de-abstraction of a digital data stream |
| US11274295B2 (en) * | 2012-08-10 | 2022-03-15 | The Broad Institute, Inc. | Methods for generating pools of variants of a DNA template |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| EP2971165A4 (de) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Entfernung von dna-fragmenten in mrna-herstellungsverfahren |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| WO2015034925A1 (en) * | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3052511A4 (de) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynukleotidmoleküle und verwendungen davon |
| US10795858B1 (en) | 2014-02-18 | 2020-10-06 | Erich Schmitt | Universal abstraction and de-abstraction of a digital data stream |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
| EP3350333B2 (de) | 2015-09-17 | 2025-08-06 | ModernaTX, Inc. | Polynukleotide mit stabilisierendem schwanzbereich |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| GB2566986A (en) | 2017-09-29 | 2019-04-03 | Evonetix Ltd | Error detection during hybridisation of target double-stranded nucleic acid |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6995017B1 (en) * | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US7018793B1 (en) * | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
| US6171820B1 (en) * | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6972183B1 (en) * | 1997-06-16 | 2005-12-06 | Diversa Corporation | Capillary array-based enzyme screening |
| US6939689B2 (en) * | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US5851804A (en) * | 1996-05-06 | 1998-12-22 | Apollon, Inc. | Chimeric kanamycin resistance gene |
| US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| KR100570935B1 (ko) | 1997-01-17 | 2006-04-13 | 맥시겐, 인크. | 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법 |
| US6183740B1 (en) * | 1997-08-13 | 2001-02-06 | Diversa Corporation | Recombinant bacterial phytases and uses thereof |
| US7078035B2 (en) | 1997-08-13 | 2006-07-18 | Diversa Corporation | Phytases, nucleic acids encoding them and methods for making and using them |
| US7432097B2 (en) | 1997-08-13 | 2008-10-07 | Verenium Corporation | Phytases, nucleic acids encoding them and methods of making and using them |
| EP1030861A4 (de) | 1997-10-31 | 2001-09-05 | Maxygen Inc | Modifizierung des virustropismius und des wirtspektrums durch virale genomdurchmischung |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| EP1555316A3 (de) | 1998-02-11 | 2008-01-30 | Maxygen, Inc. | Antigenbibliothek Immunisierung |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US6358712B1 (en) | 1999-01-05 | 2002-03-19 | Trustee Of Boston University | Ordered gene assembly |
| CA2360011A1 (en) | 1999-01-05 | 2000-07-13 | Trustees Of Boston University | Ordered gene assembly |
| US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| US6917882B2 (en) * | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| EP1151409A1 (de) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Verfahren zum bevölkern von datenstrukturen für evolutionäre-simulationen |
| US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US7024312B1 (en) * | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US7430477B2 (en) * | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US20040002147A1 (en) | 1999-12-29 | 2004-01-01 | Desantis Grace | Nitrilases |
| US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| DE60115811T2 (de) | 2000-10-25 | 2006-08-03 | Roche Diagnostics Gmbh | Amplifizierung unter Verwendung von modifizierten Primern |
| CA2846761A1 (en) | 2000-12-01 | 2002-09-06 | Verenium Corporation | Enzymes having dehalogenase activity and methods of use thereof |
| EP2292784A3 (de) * | 2001-02-21 | 2011-06-22 | Verenium Corporation | Enzyme mit Alpha-Amylaseaktivität und Verwendungsverfahren |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DK2327765T3 (en) | 2001-06-21 | 2015-07-13 | Basf Enzymes Llc | nitrilases |
| JP2005512532A (ja) * | 2001-08-03 | 2005-05-12 | ディヴァーサ コーポレイション | Ｐ４５０酵素、それらをコードした核酸及びそれらの作製と使用 |
| US6979733B2 (en) * | 2001-08-03 | 2005-12-27 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods of making and using them |
| US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| JP2005521419A (ja) | 2002-04-01 | 2005-07-21 | ブルー ヘロン バイオテクノロジー インコーポレイテッド | ポリヌクレオチド作製のための固相方法 |
| MX282672B (es) | 2002-10-10 | 2011-01-10 | Diversa Corp | Proteasas, acidos nucleicos que los codifican, y metodos de hacer y usar los mismos. |
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| EP1565205A4 (de) | 2002-11-18 | 2006-07-05 | Maxygen Inc | Interferon-alpha polypeptide und konjugate |
| JP2006524050A (ja) * | 2003-03-20 | 2006-10-26 | ダイヴァーサ コーポレイション | グルコシダーゼ、それをコードする核酸、並びにその製造および使用方法 |
| US7947817B2 (en) | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
| CN1625176B (zh) * | 2003-12-03 | 2010-04-28 | 华为技术有限公司 | 基于边缘到边缘伪线仿真协议的通信方法 |
| GB0406863D0 (en) | 2004-03-26 | 2004-04-28 | Qiagen As | Nucleic acid sequencing |
| GB0406865D0 (en) | 2004-03-26 | 2004-04-28 | Qiagen Gmbh | Nucleic acid sequencing |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| CN101115769A (zh) * | 2004-05-19 | 2008-01-30 | 马克西根公司 | 干扰素-α多肽和偶联物 |
| EP3985125A1 (de) | 2004-06-01 | 2022-04-20 | Abbott Diagnostics Scarborough, Inc. | Rekombinase-polymerase-verstärkung |
| US20060008844A1 (en) * | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| CA2587463A1 (en) | 2004-11-16 | 2006-11-30 | Avidia Research Institute | Protein scaffolds and uses therof |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| WO2006096527A2 (en) | 2005-03-04 | 2006-09-14 | Diversa Corporation | Nucleic acids and proteins and methods for making and using them |
| EP2886658A1 (de) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyaseenzyme, Nukleinsäuren zur Codierung davon und Verfahren zur Herstellung und Verwendung davon |
| CA2611859C (en) | 2005-03-15 | 2015-03-31 | Verenium Corporation | Cellulases, nucleic acids encoding them and methods for making and using them |
| EP1888633A4 (de) | 2005-05-18 | 2010-01-27 | Maxygen Inc | Entfaltete interferon-alpha-polypeptide |
| US20070292954A1 (en) * | 2006-04-21 | 2007-12-20 | The Brigham And Women's Hospital, Inc. | Generation of recombinant DNA by sequence-and ligation-independent cloning |
-
2005
- 2005-11-11 WO PCT/US2005/040748 patent/WO2006053131A1/en not_active Ceased
- 2005-11-11 EP EP05819866A patent/EP1817413B1/de not_active Expired - Lifetime
- 2005-11-11 US US11/271,562 patent/US7485423B2/en not_active Expired - Lifetime
- 2005-11-11 AT AT05819866T patent/ATE540110T1/de active
- 2005-11-11 JP JP2007541321A patent/JP2008519602A/ja active Pending
- 2005-11-11 CA CA002590245A patent/CA2590245A1/en not_active Abandoned
-
2009
- 2009-01-30 US US12/363,096 patent/US20090298130A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006053131A1 (en) | 2006-05-18 |
| EP1817413B1 (de) | 2012-01-04 |
| US20090298130A1 (en) | 2009-12-03 |
| US7485423B2 (en) | 2009-02-03 |
| EP1817413A1 (de) | 2007-08-15 |
| JP2008519602A (ja) | 2008-06-12 |
| US20060223081A1 (en) | 2006-10-05 |
| CA2590245A1 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE540110T1 (de) | Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt | |
| EP1750771A4 (de) | Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung | |
| WO2004013280A3 (en) | ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING | |
| NO20070263L (no) | Immunostimulerende oligonukleotidmultimerer | |
| ATE513843T1 (de) | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna | |
| WO2006119266A3 (en) | Human micrornas and methods for inhibiting same | |
| MA29384B1 (fr) | Acides nucleiques de liaison a la ghreline | |
| ATE544774T1 (de) | Rnai-modulation von mll-af4 und verwendungen dafür | |
| WO2007123744A3 (en) | Systems and devices for sequence by synthesis analysis | |
| WO2009108918A3 (en) | Methods and systems for social networking based on nucleic acid sequences | |
| ATE502122T1 (de) | Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation | |
| WO2008109472A3 (en) | Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof | |
| EP2514826A3 (de) | Verwendung von interferierendem RNA zur Herabregulation von spezifischen Genen oder Genenfamilie | |
| EA200800838A1 (ru) | Модуляция иммуностимулирующих свойств короткой интерферирующей рибонуклеиновой кислоты (siphk) с помощью модификации нуклеотидов | |
| ATE490260T1 (de) | Mit lipidmembran attachments verwandte oligonukleotide | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| DE602004027538D1 (de) | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon | |
| ATE356871T1 (de) | Eine methode zur in vitro molekularen evolution der proteinfunktion | |
| CY1116649T1 (el) | Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα | |
| DE60110926D1 (de) | Eine methode zur in vitro molekularen evolution der proteinfunktion | |
| ATE526398T1 (de) | Arachnocampa-luciferasen | |
| WO2007014077A3 (en) | Rnai modulation of the rho-a gene and uses thereof | |
| DK1730315T3 (da) | Polymorphismer i NOD2/Card15 gen | |
| MX2007004686A (es) | Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos. | |
| GB2432366B (en) | A method for in vitro molecular evolution of protein function |